Our final goal is to mechanistically characterize the essential role of the serotonin 5-HT2A (5HT2A) receptor and the metabotropic glutamate 2 (mGlu2) receptor as a G protein-coupled receptor (GPCR) heteromeric complex in regulating receptor trafficking, signaling, and antipsychotic-like behavior. The neurotransmitters serotonin and glutamate both have been the target of considerable attention regarding psychosis and antipsychotic drug development. Family A 5HT2A and family C mGlu2 are GPCRs that have been implicated in the pathophysiology and treatment of schizophrenia and other psychotic disorders. Atypical antipsychotic drugs, such as clozapine, olanzapine and risperidone, all have in common a high affinity for the 5HT2A receptor. Recent preclinical assays in rodents suggest that drugs that activate the mGlu2 receptor represent potential new antipsychotic medications. Our previous findings demonstrate that 5HT2A and mGlu2 maintain close molecular proximity in heterologous systems and in mouse frontal cortex. Using the combination of interdisciplinary approaches in vitro, in animal models and in postmortem human brain of schizophrenic subjects, we provide evidence that the 5HT2A-mGlu2 heteromeric receptor complex is necessary for the therapeutic responses induced by atypical and glutamate antipsychotic drugs, and is potentially involved in the altered cortical processes of schizophrenia. In order to provide a better understanding of the 5HT2A-mGlu2 complex in brain function, and the foundation for the development of more effective antipsychotic drugs, we propose to characterize the basic molecular mechanisms involved in its intracellular trafficking and signaling, as well as to investigate the antipsychotic-like behavioral responses that require expression of 5HT2A and mGlu2 as a GPCR heteromer in mouse. Our results are expected to extend our understanding of the molecular basis of psychosis, and may provide a route to the identification of new and more effective drugs for the treatment of schizophrenia and other psychiatric disorders.

Public Health Relevance

Schizophrenia is a chronic mental disorder that affects approximately one percent of the population worldwide, with similar prevalence throughout diverse cultures and geographic areas. We have discovered that two neurotransmitter receptors are expressed in close molecular proximity in the brain, and that this receptor complex is affected in schizophrenia brain. A better understanding of the structure and behavioral function of this neuroreceptor complex may lead to the identification of more effective therapeutic approaches for the treatment of schizophrenia and other psychiatric disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH084894-09
Application #
9504500
Study Section
Molecular Neuropharmacology and Signaling Study Section (MNPS)
Program Officer
Nadler, Laurie S
Project Start
2009-01-01
Project End
2019-05-31
Budget Start
2018-06-01
Budget End
2019-05-31
Support Year
9
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Physiology
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
López-Giménez, Juan F; González-Maeso, Javier (2017) Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways. Curr Top Behav Neurosci :
Lopez-Gimenez, Juan F; de la Fuente Revenga, Mario; Ruso-Julve, Fulgencio et al. (2017) Validation of schizophrenia gene expression profile in a preclinical model of maternal infection during pregnancy. Schizophr Res 189:217-218
Gaitonde, Supriya A; González-Maeso, Javier (2017) Contribution of heteromerization to G protein-coupled receptor function. Curr Opin Pharmacol 32:23-31
Fomsgaard, Luna; Moreno, Jose L; de la Fuente Revenga, Mario et al. (2017) Differences in 5-HT2A and mGlu2 Receptor Expression Levels and Repressive Epigenetic Modifications at the 5-HT2A Promoter Region in the Roman Low- (RLA-I) and High- (RHA-I) Avoidance Rat Strains. Mol Neurobiol :
Oliveras, Ignasi; Sánchez-González, Ana; Sampedro-Viana, Daniel et al. (2017) Differential effects of antipsychotic and propsychotic drugs on prepulse inhibition and locomotor activity in Roman high- (RHA) and low-avoidance (RLA) rats. Psychopharmacology (Berl) 234:957-975
Ibi, Daisuke; de la Fuente Revenga, Mario; Kezunovic, Nebojsa et al. (2017) Antipsychotic-induced Hdac2 transcription via NF-?B leads to synaptic and cognitive side effects. Nat Neurosci 20:1247-1259
Holloway, Terrell; Moreno, Jose L; González-Maeso, Javier (2016) HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice. J Vis Exp :
Baki, Lia; Fribourg, Miguel; Younkin, Jason et al. (2016) Cross-signaling in metabotropic glutamate 2 and serotonin 2A receptor heteromers in mammalian cells. Pflugers Arch 468:775-93
Younkin, Jason; Gaitonde, Supriya A; Ellaithy, Amr et al. (2016) Reformulating a Pharmacophore for 5-HT2A Serotonin Receptor Antagonists. ACS Chem Neurosci 7:1292-9
Moreno, José L; Miranda-Azpiazu, Patricia; García-Bea, Aintzane et al. (2016) Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia. Sci Signal 9:ra5

Showing the most recent 10 out of 39 publications